title: Frequent loss of pRb2/p130 in human ovarian carcinoma.
abstract: OBJECTIVE
  RB2/p130, a member of the retinoblastoma gene family, maps to human chromosome 16q12.2, a region in which deletions have been found in several human neoplasms including breast, prostatic, and ovarian carcinoma. We sought to evaluate pRb2/p130 protein expression and function in ovarian carcinoma.
  
  
  METHODS
  pRb2/p130 expression was detected by immunohistochemical and Western blot analyses in 45 primary ovarian carcinoma samples.
  
  
  RESULTS
  Immunohistochemical analysis revealed loss or decrease of pRb2/p130 expression in 18 cases (40%). pRb2/p130 expression was mostly nuclear and inversely correlated to the tumor grade (P < 0.05). Western blot analysis correlated with immunohistochemical expression. Reverse transcription-PCR followed by Southern blot analysis was performed on a representative set of 20 ovarian carcinomas. RB2/p130 mRNA levels were consistent with protein expression. We found a significant increase in the percentage of G(1)-phase-arrested cells in CAOV3 and A2780 ovarian carcinoma cell lines after transduction with an adenovirus carrying the RB2/p130 gene (Ad-CMV-RB2/p130).
  
  
  CONCLUSIONS
  These data indicate that loss or decrease of pRb2/p130 expression is a frequent event in ovarian carcinoma and is regulated mostly at the transcriptional level. Moreover, pRb2/p130 overexpression is able to arrest cell growth in ovarian carcinoma cells, suggesting the putative role of pRb2/p130 as a tumor suppressor in this malignancy.
authors.affiliation: Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, PA 19122, USA.
authors.forename: Giuseppina
authors.initials: G
authors.lastname: D'Andrilli
authors.forename: Valeria
authors.initials: V
authors.lastname: Masciullo
authors.forename: Luigi
authors.initials: L
authors.lastname: Bagella
authors.forename: Tiziana
authors.initials: T
authors.lastname: Tonini
authors.forename: Corrado
authors.initials: C
authors.lastname: Minimo
authors.forename: Gian Franco
authors.initials: GF
authors.lastname: Zannoni
authors.forename: Robert L
authors.initials: RL
authors.lastname: Giuntoli
authors.forename: John A
authors.initials: JA
authors.lastname: Carlson
authors.forename: Dianne Robert
authors.initials: DR
authors.lastname: Soprano
authors.forename: Kenneth J
authors.initials: KJ
authors.lastname: Soprano
authors.forename: Giovanni
authors.initials: G
authors.lastname: Scambia
authors.forename: Antonio
authors.initials: A
authors.lastname: Giordano
mesh_terms: D000230:Adenocarcinoma / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D015153:Blotting, Western; D002453:Cell Cycle / Q000235:genetics / Q000502:physiology; D002455:Cell Division / Q000235:genetics / Q000502:physiology; D045744:Cell Line, Tumor; D018899:CpG Islands / Q000235:genetics; D019175:DNA Methylation; D004252:DNA Mutational Analysis; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D005822:Genetic Vectors / Q000235:genetics; D006801:Humans; D007150:Immunohistochemistry; D010051:Ovarian Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D011506:Proteins / Q000235:genetics / Q000378:metabolism*; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D011993:Recombinant Fusion Proteins / Q000235:genetics / Q000502:physiology; D050717:Retinoblastoma-Like Protein p130; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection
chemical_list: D011506:Proteins; C493837:RBL2 protein, human; D012333:RNA, Messenger; D011993:Recombinant Fusion Proteins; D050717:Retinoblastoma-Like Protein p130